Literature DB >> 16827892

Oral tolerance induction by mucosal administration of cholera toxin B-coupled antigen involves T-cell proliferation in vivo and is not affected by depletion of CD25+ T cells.

Annie George Chandy1, Susanne Hultkrantz, Sukanya Raghavan, Cecil Czerkinsky, Michael Lebens, Esbjörn Telemo, Jan Holmgren.   

Abstract

Oral administration of antigens coupled to the B subunit of the cholera toxin (CTB) can dramatically reduce the amount of antigen needed for tolerance induction and has been used in several animal models to suppress conditions where the immune system overreacts to foreign and self-antigens. In this study, the cellular events following oral administration of CTB-coupled antigen was investigated. As a model system, limited numbers of CSFE-labelled cells from influenza haemagglutinin peptide (HApep) T-cell transgenic mice were transferred to wild type mice and the mice were then given CTB-coupled HApep orally. The inductive events of CTB-induced tolerance was characterized by extensive proliferation of HApep-specific T cells in the mesenteric lymph nodes (MLNs) and in the spleen. The proliferating cells up-regulated the gut homing molecule alpha4beta7 and down-regulated the high endothelial venule binding molecule L-selectin. Addition of the whole cholera toxin (CT) to CTB-HApep showed a similar pattern as CTB-HApep feeding, with antigen-specific proliferation in the MLN and spleen and expression of alpha4beta7 on the proliferating cells. However, addition of CT to CTB-HApep, produced a stronger and faster proliferative response and abrogated CTB-HA mediated oral tolerance. Feeding of CTB-HApep expanded CD25+ cells in the MLNs. CTB-induced oral tolerance could, however, not be explained by CD25+ dependent regulatory activity, as oral administration of CTB-HApep to mice depleted of CD25+ cells still gave rise to systemic tolerance. Thus, several mechanisms might co-orchestrate the systemic tolerance seen in response to feeding with CTB-coupled antigen.

Entities:  

Mesh:

Substances:

Year:  2006        PMID: 16827892      PMCID: PMC1782302          DOI: 10.1111/j.1365-2567.2006.02368.x

Source DB:  PubMed          Journal:  Immunology        ISSN: 0019-2805            Impact factor:   7.397


  45 in total

1.  The mucosal milieu creates tolerogenic dendritic cells and T(R)1 and T(H)3 regulatory cells.

Authors:  H L Weiner
Journal:  Nat Immunol       Date:  2001-08       Impact factor: 25.606

2.  Cholera toxin B subunit as a carrier molecule promotes antigen presentation and increases CD40 and CD86 expression on antigen-presenting cells.

Authors:  A George-Chandy; K Eriksson; M Lebens; I Nordström; E Schön; J Holmgren
Journal:  Infect Immun       Date:  2001-09       Impact factor: 3.441

3.  Generation of anergic and potentially immunoregulatory CD25+CD4 T cells in vivo after induction of peripheral tolerance with intravenous or oral antigen.

Authors:  K M Thorstenson; A Khoruts
Journal:  J Immunol       Date:  2001-07-01       Impact factor: 5.422

4.  "Tolerosomes" are produced by intestinal epithelial cells.

Authors:  M Karlsson; S Lundin; U Dahlgren; H Kahu; I Pettersson; E Telemo
Journal:  Eur J Immunol       Date:  2001-10       Impact factor: 5.532

Review 5.  Oral tolerance.

Authors:  P Garside; A M Mowat
Journal:  Semin Immunol       Date:  2001-06       Impact factor: 11.130

6.  Antigen-induced mucosal T cell activation is followed by Th1 T cell suppression in continuously fed ovalbumin TCR-transgenic mice.

Authors:  T Marth; S Ring; D Schulte; N Klensch; W Strober; B L Kelsall; A Stallmach; M Zeitz
Journal:  Eur J Immunol       Date:  2000-12       Impact factor: 5.532

Review 7.  Immunologic tolerance maintained by CD25+ CD4+ regulatory T cells: their common role in controlling autoimmunity, tumor immunity, and transplantation tolerance.

Authors:  S Sakaguchi; N Sakaguchi; J Shimizu; S Yamazaki; T Sakihama; M Itoh; Y Kuniyasu; T Nomura; M Toda; T Takahashi
Journal:  Immunol Rev       Date:  2001-08       Impact factor: 12.988

8.  Activation of CD25(+)CD4(+) regulatory T cells by oral antigen administration.

Authors:  X Zhang; L Izikson; L Liu; H L Weiner
Journal:  J Immunol       Date:  2001-10-15       Impact factor: 5.422

9.  Prolonged oral treatment with low doses of allergen conjugated to cholera toxin B subunit suppresses immunoglobulin E antibody responses in sensitized mice.

Authors:  C Rask; J Holmgren; M Fredriksson; M Lindblad; I Nordström; J B Sun; C Czerkinsky
Journal:  Clin Exp Allergy       Date:  2000-07       Impact factor: 5.018

Review 10.  Type 1 T regulatory cells.

Authors:  M G Roncarolo; R Bacchetta; C Bordignon; S Narula; M K Levings
Journal:  Immunol Rev       Date:  2001-08       Impact factor: 12.988

View more
  4 in total

1.  Nasal cardiac myosin peptide treatment and OX40 blockade protect mice from acute and chronic virally-induced myocarditis.

Authors:  Georgia Fousteri; Amy Dave; Bret Morin; Shaida Omid; Michael Croft; Matthias G von Herrath
Journal:  J Autoimmun       Date:  2011-02-17       Impact factor: 7.094

2.  Stable production of peptide antigens in transgenic tobacco chloroplasts by fusion to the p53 tetramerisation domain.

Authors:  Susana M Ortigosa; Alicia Fernández-San Millán; Jon Veramendi
Journal:  Transgenic Res       Date:  2009-12-02       Impact factor: 2.788

Review 3.  Cholera-like enterotoxins and Regulatory T cells.

Authors:  Christelle Basset; Fatou Thiam; Cyrille Di Martino; John Holton; John D Clements; Evelyne Kohli
Journal:  Toxins (Basel)       Date:  2010-07-06       Impact factor: 4.546

4.  Polyacrylate-Peptide Antigen Conjugate as a Single-Dose Oral Vaccine against Group A Streptococcus.

Authors:  Mohammad Omer Faruck; Lili Zhao; Waleed M Hussein; Zeinab G Khalil; Robert J Capon; Mariusz Skwarczynski; Istvan Toth
Journal:  Vaccines (Basel)       Date:  2020-01-13
  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.